PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 18th Nov 2013 08:10

AGA Rangemaster: N+1 Singer raises its target price from 150p to 175p and keeps a buy recommendation.APR Energy: Jefferies cuts target price from 1300p to 1260p retaining a buy recommendation.Atkins (WS): LIberum Capital increases target price from 1300p to 1400p maintaining a buy recommendation.Aveva: Panmure Gordon ups target price from 2374p to 2386p and keeps a hold recommendation.Bank of Georgia: Panmure Gordon raises target price from 2200p to 3000p and retains a buy recommendation.Big Yellow Group: Numis raises target price from 460p to 535p keeping an add rating.Cairn Energy: UBS moves target price from 310p to 305p and stays with its buy recommendation.Cape: JP Morgan lowers target price from 299p to 288p and maintains a neutral rating.Carr's Milling: Investec increases target price from 1710p to 1900p and maintains a buy recommendation.Diploma: Jefferies takes target price from 720p to 750p and reiterates a buy recommendation. Numis downgrades from add to hold with a target price of 697p.Drax Group: Liberum Capital raises target price from 640p to 735p upgrading to buy.Euromoney: Investec ups target price from 1200p to 1250p and reiterates a buy recommendation.Foxtons: Canaccord Genuity upgrades to buy woth a target price of 320p.Gem Diamonds: JP Morgan moves target price from 180p to 185p retaining an overweight rating.International Consolidated Airlines Group: Nomura takes target price from 335p to 380p and keeps a buy recommendation.ITE Group: Investec places its target price (prev.: 335p) under review, while keeping its buy recommendation.Lancashire Holdings: Numis raises target price from 865p to 935p and upgrades from hold to add.Lonmin: Investec ups target price from 266p to 287p, but still recommends selling.Majestic Wine: Investec raises target price from 495p to 620p and retains a buy recommendation. Panmure Gordon increases target price from 500p to 635p and stays with its buy recommendation.MITIE Group: Investec ups target price from 310p to 330p and keeps a buy recommendation.New World Resources: Jefferies shifts target price from 70p to 75p and maintains its hold recommendation.Northern Petroleum: Westhouse Securities shifts target price from 123p to 120p, while upgrading to buy.Ocean Wilson Holdings: Cantor Fitzgerald ups target price from 1345p to 1400p and stays with its buy recommendation.Ophir Energy: Canaccord Genuity ups target price from 375p to 400p and retains a hold recommendation.Partnership Assurance: Deutsche Bank reduces target price from 470p to 385p keeping a hold recommendation.SAB Miller: JP Morgan increases target price from 3270p to 3465p and leaves its overweight rating unchanged.Shire: Jefferies raises target price from 3100p to 3400p and keeps a buy recommendation.Summit Corporation: N+1 Singer moves target price from 11p to 16.3p and reiterates a buy recommendation.Ultra Electronics: UBS cuts target price from 1900p to 1820p maintaining a neutral rating. JP Morgan reduces target price from 2100p to 1920p leaving its neutral rating unaltered.Vedanta Resources: Deutsche Bank cuts target price from 1050p to 1020p retaining a hold recommendation. Credit Suisse reduces target price from 1350p to 1270p and leaves its outperform rating unaltered.Volex Group: FinnCap upgrades to hold with a target price of 90p.
More News
15 Dec 2016 12:38

Summit Therapeutics widens loss as drug development continues

(ShareCast News) - Drug discovery and development company Summit Therapeutics posted its financial results for the third quarter to 31 October on Thursday. The AIM-traded firm had cash and cash equivalents at period end of £34.6m compared to £16.3m on 31 January. Its loss for the nine months was £1

Read more
16 Nov 2016 12:28

Summit Therapeutics enrols first US patients in ezutromid trial for DMD

(ShareCast News) - AIM-listed drug discovery and development company Summit Therapeutics has enrolled its first patients in phase II proof of concept trials in the US of ezutromid in patients with Duchenne muscular dystrophy. Summit said enrolment and dosing of patients into Phase Out DMD in the UK

Read more
6 Oct 2016 14:28

Summit Therapeutics shares plummet despite positive progress

(ShareCast News) - Drug discovery and development company Summit Therapeutics presented preclinical data at the 21st International Congress of the World Muscle Society in Granada, Spain on Thursday, including further findings from its programme to develop tools to measure biomarkers of muscle health

Read more
4 Oct 2016 11:52

BUZZ-Summit Therapeutics: Best day since 2009 on Sarepta deal

** Shares in drug developer Summit Therapeutics up 58 pct after teams up with US drug co Sarepta Therapeutics to develop and market DMD drug in Europe ** Stock poised for its best day since April 2009 ** Co gets $40 mln upfront payment, could receive up to $522 million in milestone p

Read more
9 Aug 2016 11:51

Summit Therapeutics Sees Positive Phase I Trial Results For Ezutromid

Read more
21 Jun 2016 06:46

Summit Therapeutics Shows Further Positive Trial Data For Ridinilazole

Read more
17 Jun 2016 11:21

Summit Therapeutics Enrols First Patient In Phase II Ezutromid Trial

Read more
2 Jun 2016 14:30

Cash reduced, losses widen at Summit Therapeutics

(ShareCast News) - Drug discovery and development company Summit Therapeutics posted its first quarter results on Thursday, with cash reduced and losses widening. The AIM-traded firm, which is advancing therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI), had cash and ca

Read more
10 May 2016 16:46

Losses widen at Summit Therapeutics

(ShareCast News) - Drug discovery and development company Summit Therapeutics reported an increase in cash and activities in its full-year results on Tuesday, though its losses widened as it carried its projects towards commercialisation. The AIM-traded firm had cash and cash equivalents of £16.3m o

Read more
10 May 2016 11:20

Summit Therapeutics Posts Widened Loss As It Progresses Programmes

Read more
28 Apr 2016 11:11

Summit Therapeutics Gets Further US Patent For Antibiotic Ridinlazole

Read more
26 Apr 2016 11:16

Summit Therapeutics Gets Clearance To Expand Ezutromid Trial To US

Read more
30 Mar 2016 12:48

Summit reports positive results from Duchenne muscular dystrophy treatment

(ShareCast News) - Summit Therapeutics reported positive interim findings on Wednesday, from a recent Phase 1 trial of a new oral formulation of its SMT C1100 therapy for Duchenne muscular dystrophy. The AIM-traded drug discovery and development company focuses on advancing therapies for Duchenne mu

Read more
30 Mar 2016 11:06

Summit Therapeutics Gets Positive Interim SMT C1100 Test Results

Read more
7 Mar 2016 12:43

Summit Therapeutics Sees Further Positive Data For Ridinilazole

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.